Myeloid cell leukemia-1 dependence in acute myeloid leukemia: a novel approach to patient therapy

Tapan Mahendra Kadia; Hagop M. Kantarjian; Marina Konopleva

doi:10.18632/oncotarget.26579

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Reviews:

Myeloid cell leukemia-1 dependence in acute myeloid leukemia: a novel approach to patient therapy

Tapan Mahendra Kadia _, Hagop M. Kantarjian and Marina Konopleva

PDF | Full Text | How to cite

Oncotarget. 2019; 10:1250-1265. https://doi.org/10.18632/oncotarget.26579

Metrics: PDF 1766 views | Full Text 2572 views | ?

Abstract

Tapan Mahendra Kadia1, Hagop M. Kantarjian1 and Marina Konopleva1

1The University of Texas MD Anderson Cancer Center, Houston, Texas, USA

Correspondence to:

Tapan Mahendra Kadia, email: [email protected]

Keywords: AML; BCL-2; MCL-1; flavopiridol; alvocidib

Received: November 08, 2018 Accepted: December 16, 2018 Published: February 08, 2019

ABSTRACT

Acute myeloid leukemia (AML) is the most common form of acute leukemia in adults, affecting approximately 21,000 people annually (nearly 11,000 deaths) in the United States. B-cell lymphoma 2 (BCL-2) family proteins, notably myeloid cell leukemia-1 (MCL-1), have been associated with both the development and persistence of AML. MCL-1 is one of the predominant BCL-2 family members expressed in samples from patients with untreated AML. MCL-1 is a critical cell survival factor for cancer and contributes to chemotherapy resistance by directly affecting cell death pathways. Here, we review the role of MCL-1 in AML and the mechanisms by which the potent cyclin-dependent kinase 9 inhibitor alvocidib, through regulation of MCL-1, may serve as a rational therapeutic approach against the disease.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 26579

Publication Alerts

Reviews:

Myeloid cell leukemia-1 dependence in acute myeloid leukemia: a novel approach to patient therapy

Abstract